Jonas Boström

Summary

Affiliation: AstraZeneca R and D

Publications

  1. doi request reprint Oxadiazoles in medicinal chemistry
    Jonas Boström
    AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    J Med Chem 55:1817-30. 2012
  2. ncbi request reprint Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools
    J Bostrom
    Department of Medicinal Chemistry, AstraZeneca R and D Molndal, Sweden
    J Comput Aided Mol Des 15:1137-52. 2001
  3. ncbi request reprint Assessing the performance of OMEGA with respect to retrieving bioactive conformations
    Jonas Boström
    Department of Medicinal Chemistry, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    J Mol Graph Model 21:449-62. 2003
  4. ncbi request reprint A 3D QSAR study on a set of dopamine D4 receptor antagonists
    Jonas Boström
    H Lundbeck A S, Ottiliavej 9, DK 2500 Copenhagen Valby, Denmark
    J Chem Inf Comput Sci 43:1020-7. 2003
  5. ncbi request reprint Do structurally similar ligands bind in a similar fashion?
    Jonas Boström
    Department of Medicinal Chemistry, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    J Med Chem 49:6716-25. 2006
  6. ncbi request reprint Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists
    Jonas Boström
    Lead Generation Department, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Bioorg Med Chem 15:4077-84. 2007
  7. doi request reprint Exploiting personalized information for reagent selection in drug design
    Jonas Boström
    Lead Generation Department, AstraZeneca R and D Molndal, S 43183 Mölndal, Sweden
    Drug Discov Today 16:181-7. 2011
  8. ncbi request reprint MIMUMBA revisited: torsion angle rules for conformer generation derived from X-ray structures
    Jens Sadowski
    Lead Generation Department, AstraZeneca R and D, S 43183 Mölndal, Sweden
    J Chem Inf Model 46:2305-9. 2006
  9. doi request reprint Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y₁₂ receptor
    Peter Bach
    Department of Medicinal Chemistry, AstraZeneca R and D Molndal, Pepparedsleden 1, S 43183 Mölndal, Sweden
    Eur J Med Chem 65:360-75. 2013
  10. doi request reprint Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5
    Roine I Olsson
    Respiratory and Inflammation iMed, AstraZeneca R and D Molndal, SE 431 83 Molndal, Sweden
    Bioorg Med Chem Lett 23:706-10. 2013

Collaborators

Detail Information

Publications15

  1. doi request reprint Oxadiazoles in medicinal chemistry
    Jonas Boström
    AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    J Med Chem 55:1817-30. 2012
    ..g., dipole moments). To facilitate the use of these heteroaromatic rings, novel synthetic routes for ready access of a broad spectrum of 1,3,4-oxadiazoles, under mild conditions, are described...
  2. ncbi request reprint Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools
    J Bostrom
    Department of Medicinal Chemistry, AstraZeneca R and D Molndal, Sweden
    J Comput Aided Mol Des 15:1137-52. 2001
    ..Factors influencing bioactive conformational retrieval have been identified and are discussed...
  3. ncbi request reprint Assessing the performance of OMEGA with respect to retrieving bioactive conformations
    Jonas Boström
    Department of Medicinal Chemistry, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    J Mol Graph Model 21:449-62. 2003
    ..Both databases provided satisfactory results in terms of retrieval. ROCS was able to rank 35 out of 36 X-ray structures among the top 500 hits from the large database...
  4. ncbi request reprint A 3D QSAR study on a set of dopamine D4 receptor antagonists
    Jonas Boström
    H Lundbeck A S, Ottiliavej 9, DK 2500 Copenhagen Valby, Denmark
    J Chem Inf Comput Sci 43:1020-7. 2003
    ..Likewise, certain hydrogen-bond acceptors can be used to lower D(2) affinity. These observations may be exploited for the design of novel dopamine D(4) selective antagonists...
  5. ncbi request reprint Do structurally similar ligands bind in a similar fashion?
    Jonas Boström
    Department of Medicinal Chemistry, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    J Med Chem 49:6716-25. 2006
    ..We allow ourselves to draw general conclusions because our data set consists of ligands with drug-like physicochemical properties complexed to a broad spectrum of different protein classes...
  6. ncbi request reprint Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists
    Jonas Boström
    Lead Generation Department, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Bioorg Med Chem 15:4077-84. 2007
    ..The synthesis and CB1 antagonistic activities of a new series of 5,6-diaryl-pyrazine-2-amide derivatives are described. Several compounds showed antagonist potency below 10nM for the CB1 receptor...
  7. doi request reprint Exploiting personalized information for reagent selection in drug design
    Jonas Boström
    Lead Generation Department, AstraZeneca R and D Molndal, S 43183 Mölndal, Sweden
    Drug Discov Today 16:181-7. 2011
    ..The system is tailored to highlight reagents from our corporate reagent database; reagents that a chemist might not have considered based purely on their own experience...
  8. ncbi request reprint MIMUMBA revisited: torsion angle rules for conformer generation derived from X-ray structures
    Jens Sadowski
    Lead Generation Department, AstraZeneca R and D, S 43183 Mölndal, Sweden
    J Chem Inf Model 46:2305-9. 2006
    ..5 A to the X-ray structure improves from 84% to 92% in a test set of 11 027 experimental structures from the CSD. Moreover, the average RMS distance of the closest conformation to the X-ray structure improves from 0.30 to 0.22 A...
  9. doi request reprint Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y₁₂ receptor
    Peter Bach
    Department of Medicinal Chemistry, AstraZeneca R and D Molndal, Pepparedsleden 1, S 43183 Mölndal, Sweden
    Eur J Med Chem 65:360-75. 2013
    ....
  10. doi request reprint Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5
    Roine I Olsson
    Respiratory and Inflammation iMed, AstraZeneca R and D Molndal, SE 431 83 Molndal, Sweden
    Bioorg Med Chem Lett 23:706-10. 2013
    ..5 IC(50) values of <0.5 μM were discovered. Selectivity over the ventricular IKs current was monitored and selective compounds were found. Results from a rabbit PD-model are included...
  11. doi request reprint Exploiting structural information in patent specifications for key compound prediction
    Christian Tyrchan
    AstraZeneca R and D, CVGI iMED, Pepparedsleden 1, S 431 83 Molndal, Sweden
    J Chem Inf Model 52:1480-9. 2012
    ..Finally, a successful example of applying FOG analysis for designing potent ATP-competitive AXL kinase inhibitors with improved properties is described...
  12. doi request reprint Follow-on drugs: how far should chemists look?
    Fabrizio Giordanetto
    AstraZeneca R and D, CVGI iMED, Pepparedsleden 1, S 431 83 Molndal, Sweden
    Drug Discov Today 16:722-32. 2011
    ..This highlights the fact that even simple atomic variations can cause drastic changes in molecular properties responsible for therapeutic advantages...
  13. doi request reprint Novel thioamide derivatives as neutral CB1 receptor antagonists
    Jonas Boström
    Lead Generation Department, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Bioorg Med Chem Lett 20:479-82. 2010
    ..The structural series of thioamides not only showed retained CB1 potency (below 10nM), but also showed improved solubility. In addition, the neutral antagonist 2c significantly reduced body weight in cafeteria diet obese mice...
  14. doi request reprint A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor
    Peter Bach
    Department of Medicinal Chemistry, AstraZeneca R and D, Pepparedsleden 1, S 43183 Mölndal, Sweden
    Bioorg Med Chem Lett 21:2877-81. 2011
    ..The synthesis of the piperazinyl-pyridine urea derivatives and their structure-activity relationships (SAR) are described. Several compounds showed P2Y(12) antagonistic activities in the sub-micromolar range...
  15. ncbi request reprint Computational chemistry-driven decision making in lead generation
    Volker Schnecke
    Computational Lead Discovery, Department of Medicinal Chemistry, AstraZeneca R and D Molndal, S 43183 Mölndal, Sweden
    Drug Discov Today 11:43-50. 2006
    ..Striving for the best possible decision is crucial because choosing the wrong series is a costly one-way street...